Description: Talniflumate (BA -602-06), a prodrug of Niflumic acid, is a potent,orally bioactiveand selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2b-1,6 N-acetylglucosaminyltrans-ferase). Talniflumate is a Ca2+-activated Cl- channel (CaCC)
blocker and has to be converted to the active formNiflumic acid in order to exert its effects. Talniflumate can be used as an analgesic and anti-inflammatory
agent in cystic fibrosis mouse model of distal intestinal obstructive
syndrome.
References:
[1].Hyun-Ji
Kim, et al. Pharmacokinetics of talniflumate, a prodrug of niflumic
acid, following oral administration to man. Archives of Pharmacal
Research volume 19, Article number: 297 (1996)
[2].Mollereau,
et al. Agonist and Antagonist Activities on Human NPFF(2) Receptors of
the NPY Ligands GR231118 and BIBP3226. Br J Pharmacol.2001
May;133(1):1-4.
[3]. Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers?. Int J Clin Pharmacol Ther. 2017 Jan;55(1):102-108.